Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Norepinephrine

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Noradrenaline Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 17,217Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Otsuka Pharma Seeks FDA Approval For Centanafadine In ADHD
    Otsuka Pharma Seeks FDA Approval For Centanafadine In ADHD

    24 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251124043308/en/Otsuka-Pharmaceutical-Submits-New-Drug-Application-to-U.S.-FDA-for-Centanafadine-for-the-Treatment-of-ADHD-in-Children-Adolescents-and-Adults

    BUSINESSWIRE
    24 Nov 2025
    Share Share
    Long Grove Pharmaceuticals Launches Premix Norepinephrine
    Long Grove Pharmaceuticals Launches Premix Norepinephrine

    22 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/long-grove-pharmaceuticals-launches-premix-norepinephrine-302153136.html

    PR NEWSWIRE
    22 May 2024
    Share Share
    Axsome Initiates PARADIGM Ph3 Trial of Solriamfetol for the Treatment MDD
    Axsome Initiates PARADIGM Ph3 Trial of Solriamfetol for the Treatment MDD

    19 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/03/19/2848411/33090/en/Axsome-Therapeutics-Initiates-PARADIGM-Phase-3-Trial-of-Solriamfetol-for-the-Treatment-of-Major-Depressive-Disorder.html

    GLOBENEWSWIRE
    19 Mar 2024
    Share Share
    Enforcement Report - Week of August 9, 2023
    Enforcement Report - Week of August 9, 2023

    09 Aug 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-august-9-2023-9584.pdf

    FDA
    09 Aug 2023
    Share Share
    Enforcement Report - Week of May 31, 2023
    Enforcement Report - Week of May 31, 2023

    31 May 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-31-2023-56013.pdf

    FDA
    31 May 2023
    Share Share
    Enforcement Report - Week of May 24, 2023
    Enforcement Report - Week of May 24, 2023

    24 May 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-24-2023-89772.pdf

    FDA
    24 May 2023
    Share Share